Nektar Therapeutics NKTR Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's change in accrued liabilities?
- Nektar Therapeutics (NKTR) reported change in accrued liabilities of $2.33M in Q1 2026.
- How has Nektar Therapeutics's change in accrued liabilities changed year-over-year?
- Nektar Therapeutics's change in accrued liabilities increased by 91.4% year-over-year, from $1.22M to $2.33M.
- What is the long-term trend for Nektar Therapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2025), Nektar Therapeutics's change in accrued liabilities has grown at a -49.8% compound annual growth rate (CAGR), from -$22.93M to -$5.79M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.